Walled Lake Planning & Wealth Management LLC Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Walled Lake Planning & Wealth Management LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,435 shares of the biopharmaceutical company’s stock after acquiring an additional 1,165 shares during the quarter. Gilead Sciences accounts for about 2.9% of Walled Lake Planning & Wealth Management LLC’s holdings, making the stock its 8th largest position. Walled Lake Planning & Wealth Management LLC’s holdings in Gilead Sciences were worth $7,892,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. HHM Wealth Advisors LLC raised its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at about $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC increased its holdings in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD opened at $111.79 on Friday. The firm’s 50 day moving average price is $105.48 and its two-hundred day moving average price is $94.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The firm has a market cap of $139.22 billion, a P/E ratio of 302.14, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 302,785 shares of company stock worth $30,503,250 over the last ninety days. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on GILD. Morgan Stanley lifted their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, March 11th. Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Piper Sandler upped their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.